EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitLeitlinieOpen Access · CC BY 4.0

From guidelines to evidence-based practice – A German perspective on mesalazine as first-line therapy for mild-to-moderate ulcerative colitis

Elisabeth Schnoy, Axel Dignass, Matthew Gaskins, Torsten Kucharzik

Zeitschrift für Gastroenterologie · 01.10.2025 · 63 (10) · 1053-1067

DOI: 10.1055/a-2596-8934 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.10.2025. Verfasst von Elisabeth Schnoy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine III, University Hospital Augsburg, Augsburg, Germany. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Mesalamine, Practice Guidelines as Topic, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ferring Arzneimittel GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mesalazine is the first-line treatment for mild-to-moderate ulcerative colitis (UC) of any extent, as recommended by all major international and national guidelines. Approximately 85% of UC cases are classified as mild-to-moderate, making mesalazine a cornerstone therapy for the majority of patients. It rapidly induces clinical response and clinical remission, sustains steroid-free clinical, endoscopic, and histologic remission over the long term, and has a safety profile comparable to placebo. This paper reviews the recommendations for mesalazine use in the German UC guideline and provides practical advice (including do’s and don’ts) for their implementation in daily clinical practice. Examples include explaining the expected timeline and nature of the clinical response to mesalazine treatment; outlining the practical implications of the dose-dependency of the drug’s therapeutic effect; and emphasizing the importance of rectal mesalazine as the first-line treatment for proctitis. Additionally, we conducted a systematic literature search to evaluate whether mesalazine should be continued after escalation to biologics or small molecules. While no clear evidence of short-term clinical benefit was found, there was also no evidence of harm. In light of the potential long-term chemoprotective effect of mesalazine, continuation may be considered on a case-by-case basis. Lastly, we provide an overview of the various mesalazine formulations available in Germany, detailing how they are not interchangeable due to differences in drug-release profiles, excipients, and dosing strengths. Understanding these differences may help clinicians personalize treatment, improving adherence and clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeMesalaminePractice Guidelines as TopicAnti-Inflammatory Agents, Non-SteroidalHumansGermanyEvidence-Based MedicineTreatment Outcome

Substanzen

MesalamineAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Internal Medicine III, University Hospital Augsburg, Augsburg, Germany.
  • Department of Medicine I, Goethe-University, Agaplesion Markus Hospital, Frankfurt, Germany.
  • Independent public health researcher, Madrid, Spain.
  • Department of Gastroenterology, Lüneburg Hospital, Lüneburg, Germany.

Förderung

  • Ferring Arzneimittel GmbH

Zitieren

APA

Schnoy, E., Dignass, A., Gaskins, M., & Kucharzik, T. (2025). From guidelines to evidence-based practice – A German perspective on mesalazine as first-line therapy for mild-to-moderate ulcerative colitis. Zeitschrift für Gastroenterologie, 63(10), 1053-1067. https://doi.org/10.1055/a-2596-8934

Vancouver

Schnoy E, Dignass A, Gaskins M, Kucharzik T. From guidelines to evidence-based practice – A German perspective on mesalazine as first-line therapy for mild-to-moderate ulcerative colitis. Zeitschrift für Gastroenterologie. 2025;63(10):1053-1067. doi:10.1055/a-2596-8934

BibTeX
@article{Schnoy2025,
  author = {Schnoy, Elisabeth and Dignass, Axel and Gaskins, Matthew and Kucharzik, Torsten},
  title = {From guidelines to evidence-based practice – A German perspective on mesalazine as first-line therapy for mild-to-moderate ulcerative colitis},
  journal = {Zeitschrift für Gastroenterologie},
  year = {2025},
  volume = {63},
  number = {10},
  pages = {1053--1067},
  doi = {10.1055/a-2596-8934}
}
Kostenlos starten →